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Background: The model-based dynamic insulin sensitivity and secretion test (DISST)
uses fasting glucose (G0) as the basal glucose (GB) concentration when assessing insulin
sensitivity (SI). However, this model was developed in a healthy, normoglycaemic
cohort. We sought to determine the suitability the DISST model has for individuals with
established type 2 diabetes (T2D).
Methods: 14 participants with established T2D were recruited to take part in a dietary
intervention study. Insulin-modified intravenous glucose tolerance tests (IM-IVGTT) were
undertaken at week 0, 12 and 24 and were used with DISST model to identify GB. A total
of 36 tests were conducted across 12 participants throughout the study. Measured G0
and identified GB values were compared using a Kolmogorov-Smirnov (KS) and signed
rank (RS) test for the cohort.
Results: There were significant differences between the G0 and identified GB values in
this cohort (prs and pks < 0.0001), although both values were well correlated (R = 0.70).
The residual plot demonstrates that the modified model captures the behaviour of the
participants more accurately than the original model.
Conclusions: This analysis has shown that GB is an important variable for modelling the
glycaemic behaviour in T2D. These findings suggest that the original DISST model,
while appropriate for normoglycaemic cohorts, needs to model basal glucose level as a
variable for assessing individuals with established T2D.
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Type 2 diabetes mellitus (T2DM) is a metabolic disease that affects the body’s ability
to regulate glucose concentrations [1-3]. T2DM is characterized by fasting and post-
prandial hyperglycaemia [4] and causes comorbidities with significant personal and
economic cost [5]. The hyperglycaemia is attributed to a combination of impaired in-
sulin utilization (insulin resistance) and a limited ability to compensate with insulin
production (net insulin deficiency).
The ability to quantify both insulin sensitivity and insulin secretion is essential to im-
proving the understanding of the complex physiology underlying type 2 diabetes.
Mathematical models of glycaemic dynamics have been coupled with clinical data to
identify key aspects in the pathogenesis of type 2 diabetes. The dynamic insulin© 2015 Othman et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
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insulin-modified intravenous glucose tolerance test (IM-IVGTT) [6,7] and measures
the participant glucose, insulin and C-peptide responses. The DISST data modelling
and data fitting methods were customized to the clinical protocol and allow a robust
measurement of insulin sensitivity (SI) that avoids the problems encountered with
IVGTT assessment in insulin resistant patients [8-11]. The DISST SI value is highly
correlated to the euglycaemic hyperinsulinaemic clamp (EIC) SI value (R = 0.81), which
is widely regarded as the reference method [12].
However, the DISST model uses the participant’s measured fasting glucose concentration
(G0) as their basal glucose concentration (GB). The GB term in the DISST model effectively
has the role of determining the set-point towards which the modelled glucose response
tends, where this choice matches assumptions in all other model-based tests [6,9,13-15].
However, the DISST model was developed in a relatively healthy, normoglycemic cohort
[16,17]. In contrast, studies show that G0 levels and insulin concentrations are slightly
higher in the morning than their overnight “basal” levels, especially for participants with dia-
betes [18-21]. Therefore, the evidence suggests that GB and G0 should be treated as separate
entities for individuals with established diabetes as the levels are determined by relative in-
sufficiencies in SI, endogenous insulin secretion (UN) and rates of gluconeogenesis [22-24].
We sought to determine whether a novel modelling approach that identifies GB as a
variable in individuals with established type 2 diabetes more accurately reflects glucose
dynamics.Methods
Participants
Fourteen individuals with established type 2 diabetes mellitus were recruited from the
Wellington region of New Zealand to take part in an Atkins-Based low carbohydrate
dietary intervention study. Recruited participants were aged between 30 and 65 with a
BMI range of 34 to 46 kg · m−2 at baseline. Participants were excluded if they had major
physiological or psychological illness at the time of testing. Pregnant or lactating females
were also excluded. Two participants discontinued the intervention, the first citing per-
sonal reasons, and the second left the study due to a renal stone. Twelve participants each
underwent three IM-IVGTT over a 24 week period resulted in a total of 36 tests for the
study. Participants had their age and BMI recorded (median [IQR]; 47.5 [42.5, 54.5] and
40.40 [37.48, 43.48], respectively). Full demographic details and results of the intervention
study have been previously described [25]. Ethics approval for this study was provided by
the New Zealand Ministry of Health, Central Regional Ethics Committee.Clinical procedure
The clinical protocol utilised in this study was similar to the protocol defined by Ward
et al. [7]. A 0.2 g · kg−1 glucose bolus was administered at t = 1 minute and then an infusion
of insulin that was intended to replicate the insulinaemic response of a normoglycaemic in-
dividual was administered. An insulin infusion was started at t = 2 minutes at a rate of
3.5 mU · kg−1 · min−1 and was reduced to 0.5 mU · kg−1 · min−1 at t = 7 minutes. Further re-
ductions occurred at t = 17 minutes, to 0.25 mU · kg−1 · min−1, and at t = 50 minutes,
to 0.1 mU · kg−1 · min−1. The infusion of mU · kg−1 · min−1 was maintained for the
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tubes at times: t = −10, −5, −1, 0, 2, 3, 4, 5, 6, 8, 10, 12.5, 15, 20, 25, 30, 35, 40, 50, 60,
70, 80, 90, 100, 120, 140, 160, 180, 210, 240, 270 and 300 minutes. Blood samples
were assayed for glucose and insulin concentration using standard commercial assays
at an accredited laboratory.
Model
Dynamic Insulin Sensitivity and Secretion Test (DISST) Model
This analysis used the DISST models of interstitial insulin kinetics and glucose dynam-
ics [16,17]:
_Q ¼ nI
VQ
I− nC þ nIVQ
 
Q ð1Þ
_G ¼ −pG G−GBð Þ−SI GQ−GBQBð Þ þ
PX
VG
ð2Þ
where equation nomenclature is shown in Table 1.
VQ, nI and nC are defined a-priori based on anatomical functions [17,26-28] while
DISST model sets pG as a constant at 0.004 min
−1 [17].
Parameter identification
Interstitial insulin (Q) was simulated via integrating factors and a linear interpolation of I.
Q ¼ e
−
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0
nC þ nIVQ dt Q0 þ
Z t
0
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where Q0 is determined assuming a steady state at t = −10 minutes:
Q0 ¼
nI
VQ
I0
nC þ nIVQ
ð3ÞTable 1 Nomenclature of the DISST model
Variable Unit Description Role
I mU · L−1 Plasma insulin concentration Measured
G mmol · L−1 Plasma glucose concentration Measured
GB mmol · L
−1 Basal plasma glucose concentration Measured
Q mU · L−1 Interstitial insulin concentration Simulated
QB mU · L
−1 Basal interstitial insulin concentration Simulated
VQ L Interstitial insulin distribution volume a-priori
nI L · min
−1 Plasma-interstitial diffusion rate a-priori
nC min
−1 Interstitial insulin degradation rate a-priori
PX mmol · min
−1 Exogenous glucose input rate a-priori
pG min
−1 Non-insulin mediated glucose disposal rate a-priori
VG L Glucose distribution volume Identified
SI L · mU−1 · min−1 Insulin sensitivity Identified
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gate basal glucose concentration level. However, for individuals with elevated fasting
glucose, this assumption may not be accurate [18-21], and should be tested.
In this analysis, GB was identified in concert with SI and VG. The typical approach
used with the DISST model identifies only SI and VG. Thus, the outcomes of the three-
parameter (GB, SI, VG) model were compared to the outputs of the typical two-
parameter model (SI,VG).
A Gauss Newton parameter identification method was used to identify the
participant-specific models, with objective function defined:
xiþ1 ¼ xi−α JTJ
 −1
JTψ ð4Þ
where xi = [GBi, SIi,VGi]
T and i is the iteration number. The Jacobian matrix (J) and the
residual matrix (ψ) are defined:
J xið Þ ¼
δψ1
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δψ1
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δψ1
δVGi
δψ2
δGBi
δψ2
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where n is the number of measured samples, G(xi,t1) is the modelled glucose concen-
tration at t = t1 given xi, GS(t1) is the measured glucose level at t = t1.
The Jacobian was numerically evaluated using perturbations of [δGB, δSI, δVG] = [10
− 3,
108, 10− 3]. These perturbation values were 0.1% of the order of magnitude of the expected
parameter values. Glucose samples between t = 1 and t = 10 minutes were disregarded by
the identification methods, as this period is heavily influenced by mixing kinetics that are
not captured by the whole body model of glucose metabolism [17,29].
Identifying GB in concert with SI and VG can cause identified parameter trade off in
some cases [8]. The value of VG was thus limited to physiologically measured bounds
from other studies [16,17,30,31]. In particular,VG was limited to the range of [0.12Bw,
0.25Bw] where bodyweight (Bw) is measured in kg and the coefficients have units of
l · kg−1, which is a standard estimation approach linking volume to an easily measured
value. Similarly, GB was limited to a minimum of 3 mmol · L
−1.
Analysis
Model residuals and interpretation of population trends were used to assess the per-
formance of the GB identified - DISST model. The p-values are defined with signed
ranksum (prs) and Kolmogrov Smirnov test (pks) to assess median and variability. All
analysis was undertaken using MATLAB (R2013b, Mathworks, Inc., Natick, MA, USA).
Results
Figures 1 and 2 shows the individual relationships between fasting glucose, (G0), identi-
fied basal glucose (GB-ID) and identified SI from normal DISST and GB-identified
DISST model across all participants and tests. Note the bias about the 1:1 line indicat-
ing that on average, the identified, model-based basal set point for glucose was signifi-
cantly lower than the fasting rate for this cohort with diabetes. Figure 1 shows there
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Figure 1 Relationship between fasting glucose (G0) and identified basal glucose (GB-ID) across tests.
The 1:1 G0 = GB-ID line (dots) is to show the bias between approaches. The solid line has R = 0.70.
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ranksum: prs < 0.0001, Kolmogorov Smirnov: pks < 0.0001). In general, G0 was higher
than the GB-ID value, with only 4 exceptions over 36 results (11.1%). Although there
was a significant difference in the levels of GB-ID and G0, they were relatively well corre-
lated (R = 0.70), indicating moderately consistent bias in the relationship between
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Figure 2 Relationships between SI values (based on DISST and GB-identified DISST model) across
tests. The 1:1 line (dots) is to show the bias between approaches. The solid line has R = 0.83.
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values. There is a reasonably strong correlation between the SI values between normal
DISST and GB-identified DISST model (R = 0.83). The bias indicates that by identifying
basal glucose, the model captures consistently lower SI values for those with established
T2DM.
Figure 3 shows the fitted glucose profiles and measured glucose data from 3 different
participants. It also shows that the identified GB-ID levels are well below than G0 as
depicted in Figure 1. Figure 4 illustrates the residual errors of both the typical DISST
model and the proposed three parameter identified model that identifies basal glucose.
Note that the glucose samples taken within 10 minutes of glucose injection were
ignored due to un-modelled mixing effects.Discussion
This is the first study to demonstrate that glucose excursions are more accurately mod-
elled using basal glucose as the variable in the DISST model, rather than fasting glucose
for individuals with established type 2 diabetes. The typical approach employed when
using the DISST model defines the fasting glucose (G0) as the basal glucose0
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Figure 3 Blood glucose participant-specific profile (G(t)) for participants 2, 7, 10 with normal DISST
and modified DISST identifying GB.
10 50 100 150 200 250 300
−3
−2
−1
0
1
2
3
 
 
Time [min]
ψ
ti
G
B
 identified−DISST
DISST
Figure 4 Residual error (mean and standard error, SE = SD/√N) between the measured glucose data
and the response model by Equation 2. The residuals reflect model accuracy after bolus dosing and
mixing errors are passed.
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tends towards the measured basal value. However, this analysis has shown that this as-
sumption is not valid for a cohort with established diabetes. This discrepancy in the as-
sumption is evidenced by the significant distinction in the values of G0 and GB that
reduces as the participant glycaemic control improved across the time points of the
dietary intervention study [25]. Figure 1 shows that while most participants had ele-
vated fasting glucose levels, the identified basal level was often much closer to a lower
value seen in healthy subjects. In particular, 14 of the 36 GB values identified were in
the normal reference range of 4–5.6 mmol∙L−1 [32] while only two of 36G0 values were
in that range.
However, there were some participants for whom GB-ID remained very high through-
out the intervention. Of the three participants that exhibited GB-ID values greater than
9 mmol · L−1, two were first diagnosed 10 years prior to the trial. In contrast, the mean
duration of diabetes for the whole cohort was 4.4 years (SD = 1.0 year). This outcome
indicates a possible mechanism of dysfunction in type 2 diabetes that develops during
the course of the disease, and matches growing dysfunction over time in these individ-
uals. However, this study lacks the numbers required for conclusive proof of this trend.
Figure 2 shows the effects of insulin sensitivity (SI) values have from identified GB
values are significantly lower than G0 values particularly for these type 2 diabetes par-
ticipants. Hypothetically, if models to set GB to be equal to G0, SI will account for low
glucose level rather than GB and is thus modelled as a higher SI value. A recent study
shows that the type 2 diabetes subjects have SI values in the magnitude of 2–4 × 10−4 L ·
mU−1 · min−1 [16]. Although, there is not enough evidence to prove the agreeable range of
SI value for type 2 diabetes participants, it is understandable that lower SI value contrib-
utes to the pathogenesis of type 2 diabetes as SI is inversely proportional to insulin resist-
ance (IR) [3].
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typical two-parameter (SI, VG) and three-parameter (GB, SI, VG) DISST model. While
the typical two-parameter DISST model fails to fully capture the responses of the par-
ticipants, the amended three-parameter model captures the behaviours more closely.
This outcome is confirmed by the residual plots in Figure 4 that indicate a much
smaller, yet consistent trend about the measured data. This change implies the modified
model captures previously un-modelled effects or poor a-priori estimates in the inter-
stitial insulin kinetic model.
The original DISST model was developed [17] and validated [12] in relatively normo-
glucose tolerant cohorts. In these cohorts, the incidence of impaired fasting glucose
was relatively low, and thus, the assumption of G0 equals to GB was well founded.
However, the glycaemic behaviour of the cohort used in this analysis showed that this
assumption was most likely to be invalid. In particular, the lower glucose levels
achieved in the later part of the test would be falsely attributed to insulin sensitivity ra-
ther than a GB value that was lower than G0. The significantly biased residuals showed
in Figure 4 show that the typical DISST model cannot capture all dynamics of this co-
hort without identifying GB directly.
Overall, these results indicate that the original two-parameter approach, while appro-
priate for normoglycaemic cohorts [16,17], is less suitable for individuals with estab-
lished type 2 diabetes. Furthermore, it is most likely that the outcomes of this study
would be applicable to pre-diabetic individuals that have elevated blood glucose. How-
ever, this assertion remains to be determined.
Neither DISST approach accurately captures the peak value of the measured blood
glucose data. This particular result was due to the disregarded glucose data within
10 minutes of glucose injection. This data was rejected due to the unmodelled effects
of intravascular mixing [29]. A second compartment to model local/global mixing kin-
etics could have been added. However, this addition was deemed unnecessary, as such
compartments do not add value to the DISST modelled outcomes [17]. The approach
used was intended to avoid over-fitting to mixing effects or fitting the simple DISST
model of global glucose dynamics to the local glucose mixing data.
Although, this analysis was done in a small cohort, the outcomes are significant as it
has shown that GB is an important variable when modelling the glycaemic behaviour in
type 2 diabetes. It also showed that GB can be quite different to the typically assumed
G0 value, and that it may also have some diagnostic value. These findings suggest that
the GB value should be treated as a variable in DISST model for this cohort. Further
validation in a much larger cohort will provide a solid foundation for these findings.Conclusions
This analysis has shown the presence of a dysfunction in the basal (set-point) glucose
in individuals with type 2 diabetes. The magnitude of the dysfunction has been shown
to be linked to insulin sensitivity and the degree of fasting glucose. This analysis sug-
gests that the basal glucose is a more appropriate variable for individuals with type 2
diabetes, as using the fasting glucose measurement as the basal set-point was shown to
be a poor assumption for this cohort - although this requires confirmation in a larger
study with a clamp as the reference.
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